Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Apple Turns 50: From Garage Startup to AI Crossroads 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
 and Lead Plaintiff Deadline - January 3, 2017 - EconoTimes)
NEW YORK, Dec. 29, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed against Cempra Inc. (“Cempra” or the “Company”) (NASDAQ:CEMP) and certain of its officers. This class action is on behalf of a class consisting of all persons who purchased Cempra between May 1, 2016 and November 1, 2016, both dates inclusive (the "Class Period").
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
On November 2, 2016, the U.S. Food and Drug Administration reported its preliminary review of Cempra’s drug, solithromycin, to treat community-acquired bacterial pneumonia and specified a significant safety signal for hepatotoxicity. Following this news, Cempra stock dropped $9.71 per share or over 58% to $6.95 on November 2, 2016.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (1) one of Cempra’s lead product candidates, solithromycin, posed significant safety risks for hepatotoxicity; and (2) consequently, Cempra’s public statements were materially false and misleading at all relevant times.
No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/cemp or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Cempra, you have until January 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
